NanoTEST-Development of methodology for alternative testing strategies for the assessment of toxicological profile of nanoparticles used in medical diagnistics (NanoTEST)

 

Acronym: NanoTEST
Title: “NanoTEST-Development of methodology for alternative testing strategies for the assessment of toxicological profile of nanoparticles used in medical diagnistics” (NanoTEST).
Status: Active
Funding Organization: European Union
NCSR D

Role:

Participant nr 7, Demokritos will contribute to WP4 (mathematical modelling and computational methods)
Leader in charge: C. Housiadas
Start Date: 1/4/2008
Duration: 48 months
Project

Website:

http://www.nanotest-fp7.eu/AboutUs/tabid/1570/language/en-US/Default.aspx
Summary Nanoparticles (NP) have unique, potentially beneficial properties, but their possible impact on human health has not been adequately assessed. The main goal of NANOTEST is to develop alternative high-throughput testing strategies using in vitro and in silico methods to assess the toxicological profile of NP used in medical diagnostics. The specific aims are to: 1. Define NP properties and fully characterize NP to be used 2. Study NP interactions with molecules, cells and organs and develop methods to study the toxicological potential of NP 3. Validate in vitro findings in short-term in vivo models and study particle effects in animals and (ex vivo) in humans to assess individual susceptibility to NP. 4. Develop mathematical (computational) models to enable in silico methods for NP-biological interactions. The experimental part of the project addresses NP characterization and key elements in evaluation of NP uptake, exposure and toxicology. NANOTEST integrates the investigation of toxicological properties and effects of NP in several target systems by developing a battery of in vitro assays using cell cultures, organotypic cell culture and small organ fragments (ex vivo). The computational part of the project includes QSAR and Physiologically Based Pharmacokinetics Modelling (PBPK). With the help of computational, in silico assays, NanoTest will evaluate toxic effects and interactions of NP and biofluids used in nanomedicine. Separate WPs will be dedicated to dissemination and to effective administrative and scientific management.